Dr. James Krueger is Head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York. He also serves as Physician and Co-Director of the Center for Clinical and Translational Science and Chief Executive Officer of The Rockefeller University Hospital. Dr. Krueger earned his undergraduate degree from Princeton University, a PhD in virology and cell biology from The Rockefeller University, and a medical degree from Cornell University Medical College. He completed his internal medicine internship and dermatology residency at Cornell and is board-certified by the American Board of Dermatology.

Dr. Krueger led the first clinical trials using targeted immune antagonists in psoriasis, demonstrating that depletion of pathogenic T cells from skin lesions could reverse the disease phenotype. His research has expanded to include immune-mediated skin diseases such as hidradenitis suppurativa and atopic dermatitis. His team applies immune-based therapies and pharmacogenomic approaches to uncover human populations’ disease mechanisms and therapeutic responses. A strong proponent of human-based, bidirectional translational research, Dr. Krueger continues to lead efforts to define inflammatory pathways in skin disease that cannot be replicated in animal models.